Overview

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Status:
Recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination therapy of Chidamide plus Decitabine Plus Camrelizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese PLA General Hospital

Treatments:

Decitabine